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Background: Genetic alterations could be responsible lung cancer, the leading cause of worldwide cancer death.
Methods: This study investigated gene mutations in a Han Chinese family of lung cancer using the whole genome
exome sequencing and subsequent Sanger sequencing validation and then confirmed alteration of prominin 1
(PROM1) and cyclic AMP-response element binding protein-regulated transcription co-activator2 (CRTC2) in blood
samples of 343 sporadic lung cancer patients vs. 280 healthy controls as well as in 200 pairs of lung cancer and the
corresponding normal tissues using PCR-restriction fragment length polymorphism and directed DNA sequencing
of PCR products.
Results: The data showed PROM1 (p. S281R) and CRTC2 (p. R379C) mutations, in 5 and 2 cases of these 343 sporadic
lung cancer patients, respectively. Notably, these mutations were absent in the healthy controls. Furthermore, in the
200 lung cancer and the matched normal tissues, PROM1 mutation occurred in 3 patients (i.e., one squamous cell
carcinoma and two adenocarcinomas) with a mutation frequency of 1.5%, while CRTC2 mutation occurred in 5 patients
(two squamous cell carcinomas and three adenocarcinomas) with a mutation frequency of 2.5%.
Conclusions: The data from the current study demonstrated novel PROM1 and CRTC2 mutations, which could promote
lung cancer development.
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Lung cancer is a significant worldwide health problem,
accounting for 13% (1.6 million) of the total cancer cases
and 18% (1.4 million) cancer deaths [1]. In China, data
from the most recently retrospective sampling survey
showed that the rate of lung cancer death rate was
30.83/105 (41.34/105 for men and 19.84/105 for women)
[2]. The overall five year survival rate of lung cancer re-
mains approximately 15% worldwide, driven by the ma-
jority of cases diagnosed at advanced stages, resulting in
non-resectable lesions [1]. Tobacco smoking is the pre-
dominant risk factor for both small cell lung cancer and
non-small cell lung cancer (NSCLC) [3]. However, to
date, the defined pathogenesis of lung cancer remains to
be determined because only a small fraction of tobacco* Correspondence: weimi003@yahoo.com
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stated.smokers have developed lung cancer, but a certain percent-
age of lung cancer patients are never smokers, indicating
that there is individual variation in cancer susceptibility in
the general population and there are other factors, such as
genetic factors or host contribution to a predisposition of
lung cancer development [4]. Another risk factor in lung
cancer development is familial aggregation and history,
which associated with 73% increase (95% confidence inter-
val [95%CI]: 50%-100%) in lung cancer risk in women and
71% increase (95%CI: 49-96%) in men [5]. Individuals with
the first-degree relative lung cancer had a 1.51-fold in-
crease in lung cancer risk compared to individuals without
a family history (95%CI: 1.39-1.63) [6]. Thus, lung cancer
risk models using epidemiologic data have been developed
and the most parsimonious models for both ever and never
smokers include a family history as a lung cancer risk [7].
Indeed, lung cancer can be aggregated in the family
and inherited and appears to be the result of an interaction
of multiple genes and environmental factors. Thus, searchThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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needed. Previous studies showed that several tumor sup-
pressor genes were inactivated in lung cancer patients,
including TP53 [8] RB1 [9,10], and PTEN [11], while infre-
quent activating mutations or amplifications of PIK3CA,
EGFR and KRAS, and MYC did occur in certain lung can-
cer patients [12]. Recent genome-wide association studies
(GWAS) identified some loci that associated with lung
cancer development [13,14]. Chromosomal region 15q24-
25.1, containing nicotinic acetylcholine receptor sub-unit
genes, has been associated with increased risk of lung can-
cer in ever smokers [13,14]. Linkage analysis in families
with aggregation of lung cancer showed a region on
chromosome 6q23-25 associated with risk of lung cancer
[15]. These data plus data among individuals with a family
history of lung cancer indicate that the relative risk of lung
cancer associated with markers in this region is much
higher in familial cases compared to the relative risk ob-
served among sporadic cases [16,17].
Thus, in this study, we detected gene mutations in a
Han Chinese family of lung cancer using the whole
genome exome sequencing [18] and subsequent Sanger
sequencing validation and then confirmed these gene alter-
ations in blood samples of 343sporadic lung cancer
patients vs. 280 healthy controls as well as in 200 pairs of
lung cancer and the corresponding normal tissues using
PCR-restriction fragment length polymorphism and di-
rected DNA sequencing of PCR products.
Results
Detection of PROM1 T/G and CRTC2 G/A mutations in
members of lung cancer family using whole genome
Exome sequencing
In this study, we performed whole genome Exome
sequencing on genomic DNA samples of the four af-
fected and unaffected relatives in this lung cancer family
(Table 1). To identify potential genetic variants associated
with lung cancer development, we generated an average of
4.9 Gb of DNA sequence with 50X average coverage per
individual as single-end, 90-bp reads and the fraction of
effective bases on target was about 50% with a minimum
54-fold of average sequencing depth on the target. At this
depth of coverage, more than 97% of the targeted bases
were sufficiently covered to pass the thresholds of variant
calling. We then compared the variants with the Han
Chinese Beijing SNPs from dbSNP132 and the 1000
Genome Project. This generated a total of 57 genetic
variants (including 55 non-synonymous SNPs and 2 splice)
that were shared by the two patients, but absent in the
two healthy members, which were predicted to potentially
have a functional impact on the gene expression. After
that, we directly sequenced PCR-products to validate these
57 variants and obtained accuracy of 67% (38/57) for those
variants. We found that mutations of PROM1 and CRTC2in two lung cancer patients of family cases, but absent in
the two healthy members (Table 1).
Validation of genetic variants
To confirm the 38 validated genetic variants, we per-
formed PCR-restriction fragment length polymorphism
(PCR-RFLP) analysis of blood samples from 343 unrelated
sporadic lung cancer patients and 280 healthy controls
(Table 2). This cohort of 343 lung cancer patients had a
mean age of 62.04 years old (ranged between 30 and 84
years) with 63.56% of men and 36.44% women, whereas the
280 control individuals had a mean age of 59.98years old
(ranged between 35 and 80 years) with 69.64% men and
30.64% women. Age and gender between cases and con-
trols were well balanced. We found mutations in PROM1
and CRTC2 in these two family NSCLC cases (Figure 1 and
Table 1). PROM1 mutation was a T to G change, resulting
in an S281R amino acid change. The PROM1 mutation was
validated in 5 samples, including 3 adenocarcinomas
(ADC) and 2 squamous carcinomas (SCC), with mutation
rate of 1.4% (Table 3). Moreover, CRTC2 mutation was vali-
dated with a G to A change, resulting in an R379C amino
acid change (Table 3) in two lung cancer samples, including
two ADCs, with mutation rate of 0.5%. However, both gene
mutations were absent in these 280 controls.
In addition, we further verified PROM1 and CRTC2
mutations in an additional 200 pairs of lung cancer and
the matched normal tissue specimens (Table 4). We
found PROM1mutation in 3 pairs of lung cancers and nor-
mal tissues, including 1 SCC and 2 ADCs with mutation
frequency being 1.5% and CRTC2 mutation in 5 pairs of
lung cancers and normal tissues, including 3 ADCs and 2
SCCs with mutation frequency being 2.5%. All mutations
were further confirmed by direct DNA sequencing of PCR
products (Figure 1 and Table 3).
Discussion
In the current study, we sequenced and compared the
whole genome coding regions of genes in two lung can-
cer patients and two healthy family members and then
filtered the benign changes using public databases, in-
cluding the 1000 Genome Project and dbSNP132. Use of
the second-generation sequencing technique produced a
high level of coverage with higher accuracy and allows
more regions of a genome to be sequenced in very cost
effective manner. We successfully identified PROM1 and
CRTC2 mutations. Our data are novel and mutation of
these two genes had not been previously reported in
lung cancer. After that, we confirmed our data in blood
samples of 343 lung cancer patients, but not in 280
healthy controls. These two gene mutations were not re-
ported in the 1000 Genomes data and dbSNP132.
PROM1 is localized at chromosome 4p15.32 and con-
tains 27 exons to code CD 133 protein. To date, the






















II4 Male 65 Frequent Former 1095 COPD, bronchiectasis Adenocarcinoma T1aN0M0 Moderate 841 T > G S281R 1135G > A R379C
III1 Male 51 Frequent Former 365 None Adenocarcinoma T1bN0M0 Poor-moderate 841 T > G S281R 1135G > A R379C
III4 Female 37 Never Never None N/A N/A N/A None None None None


















Table 2 Clinicopathological features of 343 sporadic
NSCLC cases and 280 healthy controls
Lung cancer Control
Characteristics N(%) N(%)








Pack years (median, range) 432(20–732) N/A
Histological types
Adenocarcinoma 120(34.98)










Moderate and poor-moderate 121(36.45)




a including: 11 small cell lung cancer; bfor non-small cell lung cancer.
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though it is a member of five-transmembrane glycopro-
teins. The latter proteins specifically localize to plasma
membrane protrusions. CD133 protein has two short
N (extracellular)- and C (cytoplasmic)-terminal tails,
and two large N-glycosylated extracellular loops (be-
tween TM2 and −3,and TM4 and −5). PROM1 can
translate into 7 isoforms of CD133 protein through the
alternative splicing in human tissues and the alterna-
tively spliced exons in the coding region only affect the
short N- and the C-terminal domains [19,20]. CD133
is expressed in various normal and stem cells; thus, it
was classified as a marker of primitive hematopoietic and
neural stem cells. Recently, rapidly accumulated evidence
indicates that CD133 had been described as the most im-
portant marker inherent to a number of types of cancer
stem cells (CSCs) [21-24]. These CSCs can initiate thetumors with performing unique functions, such as asym-
metric division, self-renewal, drug resistance and quies-
cence [25]. A previous study reported that a rare
population of tumorigenic cells in small cell and non-
small cell lung cancer expressed CD133 protein [26].
Lung cancer contained a rare population of CD133+
CSCs able to self-renew and generated an unlimited pro-
geny of non-tumorigenic cells [27]. Cui et al. investigated
several human lung cancer cell lines and found that
CD133 was a marker for the small cell lung cancer and
had stem cell-like features, such as self-renewal, dif-
ferentiation, proliferation and tumorigenic capacity
[25]. PROM1 mutations, including p.R373C, p.Q576X,
p.G614fsX626, and p.Y452fsX12, were associated with
a heterogeneous group of inherited retinal disorders with
autosomal recessive and dominant inheritance patterns
[26,28]. In our current study, we identified somatic PROM1
mutation (p.S281R) in 8/550 lung cancer patients and this
novel PROM1 mutation was a T to G change, resulting in
an S281R amino acid change. All of the 8 patients had
non-small cell lung cancer (i.e., 5 adenocarcinomas and 3
SCCs), five of which developed lung cancer at the age
younger than 60 years old and two of which were classified
as stage IV disease with poor differentiation. The mutation
of PROM1 is novel in lung cancer and further study will
investigate the role of CD133 protein in lung cancer devel-
opment and progression.
Furthermore, CRTC2 is localized at chromosome
1q21.3 and codes a 693 amino acid protein, namely
CRTC2 [29]. CRTC2 protein contains an N-terminal
GREB-binding domain (CBD), a central regulatory (REG)
domain, a splicing domain (SD), and a C-terminal domain
(TAD). CRTCs have shown to induce expression of cyclic
AMP-responsive genes [30]. CRTCs are sequestered in the
cytoplasm through phosphorylation-dependent interac-
tions with 14-3-3 proteins. In the absence of AMPK activ-
ity, CRTC2 is dephosphorylated and translocated into the
nucleus where it associated with CREB and induces ex-
pression of the target genes [31]. It has reported that
CRTC2 was able to regulate gluconeogenesis by integrat-
ing calcium and metabolic signaling through calcineurin
and AMPK/SIK kinase families [32]. Another study identi-
fied LKB1 as an essential activator for the AMPK gene
family and a key regulator for CRTC2 transcriptional ac-
tivity [33], while Shaw et al. demonstrated that SIKI may
participate in mediating LKB1 tumor suppressor activity
[34]. Ji et al. found that LKB1 mutations are detected
in human tumor samples, including lung cancer [35].
Komiya et al. found enhanced activity of CRTC1 in LKB1-
null lung cancer [36]. Brown et al. reported CRTC2 play
an important role in breast cancer of postmenopausal
women [37]. In our current study, we found somatic
CRTC2 mutation in 7/550 lung cancer patients. This
novel mutation site could change G to A and result
AB
Figure 1 Somatic gene mutations in III-1 patient. A, PROM1mutation. B, CRTC2 mutation. Tumor genomic DNA of the affected family,
genomic DNA of blood sample from lung cancer patient, genomic DNA from lung cancer and the matched normal tissues.
Table 3 Clinicopathological features of patients with PROM1 and CRTC2 mutations
Patient Gender Age (yrs.) Type T N M Stage Differentiation Tumor size (cm) Family history Smoking status Pack years
PROM1
LCa-15 M 58 ADC 1a 0 0 IA Poor 1.2 × 1 × 0.8 No Never
LC-116 M 70 SCC 4 0 0 IIIA Poor-moderate 13.5 × 12 × 6 Yes Current 182
LC-122 F 59 ADC 2a 1 1b IV Poor 4.3 × 2.3 × 3 No Never
LC-215 M 68 SCC 2b 1 0 IIB Poor 6.1 × 4.9 × 5 No Current 546
LC-275 F 54 ADC 4 2 1a IV Poor 17 × 11 × 4.1 No Never
LCTb-17 M 58 ADC 2a 1 0 IIA Moderate 4 × 3.5 × 3.5 No Current 182
LCT-51 M 61 SCC 1a 0 0 IA Poor 2 × 1.5 × 1.4 No Current 364
LCT-181 F 56 ADC 2a 1 0 IIA Moderate-well 4 × 3 × 3 No Never
CRTC2
LC-207 M 72 ADC 2a 0 0 IB Moderate 2.3 × 3.4 × 2 No Current 365
LC-250 F 65 ADC 2a 1 0 IIA Poor-moderate 4 × 4 × 3.5 No Never
LCT-81 F 57 ADC 2a 0 0 IB Poor-moderate 3 × 2.5 × 2.5 No Never
LCT-94 M 69 SCC 1b 0 0 IA Poor 2.5 × 1.5 × 1.0 No Current 500
LCT-111 M 52 SCC 2a 1 0 IIA Poor-moderate 4 × 3.5 × 2.5 No Current 280
LCT-160 M 41 ADC 2a 1 0 IIA Moderate 4 × 3.5 × 4 Yes Never
LCT-171 F 69 ADC 2a 0 0 IB Poor-moderate 4 × 4 × 3 No Never
ablood sample of lung cancer; btissue sample of lung cancer and matched normal lung tissue.
ADC, adenocarcinoma; SCC, squamous cell carcinoma.
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Table 4 Clinicopathological features of these 200
sporadic lung cancer tissues
Lung cancer
Characteristics N(%)







Pack years (median, range) 741.94(10–3000)
Histological type
adenocarcinoma 95(47.50)










Moderate and poor-moderate 100(50.51)




aincluding: 2 neuroendocrine carcinoma.
bfor non-small cell lung cancer.
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stage I and II non-small cell lung cancer (i.e., 5 adenocar-
cinomas and 2 SCCs) without metastasis. However, it
remains unknown what function of CRTC2 protein plays
in lung cancer and further studies are warranted.
Conclusions
In summary, our current study identified and confirmed
novel mutations of PROM1 and CRTC2inNSCLC patients.
Since the numbers affected patients are too small, we don’t
know whether these mutations can affect survival of pa-
tients. Further studies will investigate the role of these two
proteins in lung cancer development and progression.
Methods
Study population
This study included a four-generation Chinese Han fam-
ily with lung cancer cases that had 13(6 living) familymembers (Figure 2; Table 1). The proband (II-4) was
a 65-year-old man who had been diagnosed with
adenocarcinoma of the lung in 2012 with a 10-year
history of chronic obstructive pulmonary disease (COPD)
and bronchiectasis. He had smoked for the past 38 years
with approximately 1095 pack per year. Biochemical
examination showed an increased CEA (8.97 ng/mL,
normal < 5 ng/mL), while CT scanning showed a single
nodule with 1.5 × 1.5 × 1.0 cm in the apicoposterior seg-
ment of the left upper lobe. This proband’s 51-year-old
nephew (III-1) presented with cough, hemoptysis and
dyspnea. CT scanning confirmed unilateral mass in the
superior segment of the right lower lobe. In 2009, he
underwent an open lung lobectomy and the result of
histopathological examination confirmed as lung adeno-
carcinoma. In this family, other members also died of
lung cancer (II-2), hepatocarcinoma (I-2, II-3, III-2), or
gastric cancer (II-5).
Furthermore, to confirm gene mutations in lung can-
cer of this family members, we recruited 343sporadic
lung cancer patients vs. 280 healthy controls as well as
200 pairs of lung cancer and the corresponding nor-
mal tissues from The West China Hospital of Sichuan
University, The Second People’s Hospital of Sichuan, and
The Seventh People’s Hospital of Chengdu, Chengdu,
China between March 2010 and June 2012. All of the
sporadic lung cancer patients and the healthy controls
were non-related and were of Chinese Han ethnicity
(Table 2). Those with secondary lung cancer or other ser-
ious disease were intentionally excluded. The diagnosis
was confirmed by histopathological examination of the
resected or biopsy tissue specimens in all cases. The demo-
graphic and clinical information were collected, including
sex, age at admission, tobacco smoking, histological diag-
nosis, tumor-node-metastasis clinical stage according to
the American joint committee on cancer 2010 guidelines
[38,39]. The study was approved by the Ethics Committee
of West China Hospital of Sichuan University and all par-
ticipants provided informed consent.
DNA samples
Peripheral blood collected from patients and controls
into an anticoagulation tube and stored at −80°C until
use. Genomic DNA was then extracted using a commercial
DNA isolation kit from Bioteke (Beijing, China) according
to the manufacturer’s instructions. Tumor tissues were
fixed in formalin and embedded in paraffin and then sec-
tioned for hematoxylin and eosin staining. Pathologists
then identified areas of adequate tumor lesion (>70%) for
DNA extraction. The normal lung tissue of the patients
obtained during surgical resection represented lung tissue
located more than 5 cm from tumor lesions. Genomic
DNA was extracted using the Tissue Kit (Qiagen, Valencia,
CA) according to the manufacturer’s protocol.
Figure 2 Pedigree of this lung cancer family. Hepatocarcinoma occurred in I-2, II-3, and III-2; lung cancer in II-2, II-4, and III-1; and gastric
cancer in II-5.
He et al. Molecular Cancer 2014, 13:19 Page 7 of 9
http://www.molecular-cancer.com/content/13/1/19Whole genome exome capture and massively parallel
DNA sequencing
We then performed a whole genome exome sequencing
to identify the disease-causing genetic variant for this
lung cancer family. Briefly, 15 μg of genomic DNA sam-
ples from each of these four individuals (II-4, III-1, III-4,
and IV-1) were separately sheared into approximately
200 to 300 bp DNA fragments by Covaris, and adapters
were then ligated to both ends of the resulting DNA
fragments and amplified by ligation-mediated PCR (LM-
PCR), purified, and hybridized to the NimleGen 2.1 M
human exome array for enrichment, non-hybridized
fragments were then washed out. Both non-capture and
capture LM-PCR products were subjected to quantitative
PCR to estimate the magnitude of enrichment. Each cap-
ture library was then loaded on Hiseq2000 platform, and
high-throughput sequencing was performed for each cap-
tured library independently to ensure that each sample at
least 50-fold coverage. Raw image files were processed by
Illumina base calling Software 1.7 for base calling with de-
fault parameters and the sequences of each individual
were generated as 90 bp paired-end reads.
Sequencing reads were aligned to the human genome
(hg19) as the reference genome sequence, together with its
gene annotation that was downloaded from the UCSC
database (http://genome.ucsc.edu/). Single nucleotide poly-
morphisms (SNPs) were identified by SOAPsnp [40] and
small insertion/deletions (InDels) were detected by SAM
tools [41]. SNPs and indels were defined based on satisfac-
tion of the following: i) The consensus quality score
was bigger than Q20 (the quality score is a Phred score,
generated by the program SOAPsnp12, quality score 20represents 99% accuracy of a base call); ii) The depth
of supported reads at that locus was no less than 4X
and no more than 1000X; and iii)The distance be-
tween two SNPs no less than 5. The changes that were
shared in the two affected individuals, but absent in
the two unaffected individuals were obtained by fur-
ther comparison of the variants of each of the four
individuals. All changes were filtered against the Han
Chinese Beijing SNPs in the dbSNP132, and the 1000
Genome Project (February 28, 2011 releases for SNPs and
February 16, 2011 releases for indel http://www.1000
genome.org). All variants were then confirmed by direct
DNA sequencing of polymerase chain reaction (PCR)
product (BigDye® Terminator v3.1 Cycle Sequencing Kits;
Applied Biosystems, Foster City, CA).
Validation of gene mutations
To further verify the genetic variants identified in these
two lung cancer patients sporadic lung cancer patients
and the healthy controls, we performed PCR according
to the manufacturer’s instructions. Primers were synthe-
sized by using the on-line software (http://frodo.wi.mit.
edu/primer3/) for PCR amplification of variants identi-
fied via exome sequencing. The primers of PROM1 mu-
tation were 5′-GACCGCAGGCTAGTTTTCAC-3′ and
5′-CTTGCAGTGTGTCCCTCTCA-3′ and the primers
of CRTC2 mutation were5′-GAGGAGGAAGAGGAG
GAGGA-3′ and 5′-CTAAGCAATCCCAACCTCCA-3′.
PCR products were then digested overnight with specific
restriction enzyme MspI and separated by a 6% poly-
acrylamide gel electrophoresis and stained with 1.5 g/l of
argent nitrate to visualize both PROM1 T/G and CRTC2
He et al. Molecular Cancer 2014, 13:19 Page 8 of 9
http://www.molecular-cancer.com/content/13/1/19G/A mutations. The genotypes and all mutations were
confirmed by the DNA sequencing analysis (BigDye®
Terminator v3.1 Cycle Sequencing Kits; Applied Biosys-
tems, Foster City, CA). Approximately 10% of the cases
were randomly selected for the repeated assays and the
results were 100% concordant.
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